129 related articles for article (PubMed ID: 12532338)
1. Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer.
DuHadaway JB; Lynch FJ; Brisbay S; Bueso-Ramos C; Troncoso P; McDonnell T; Prendergast GC
J Cell Biochem; 2003 Feb; 88(3):635-42. PubMed ID: 12532338
[TBL] [Abstract][Full Text] [Related]
2. The putative tumor suppressor BIN1 is a short-lived nuclear phosphoprotein, the localization of which is altered in malignant cells.
Wechsler-Reya R; Elliott K; Herlyn M; Prendergast GC
Cancer Res; 1997 Aug; 57(15):3258-63. PubMed ID: 9242458
[TBL] [Abstract][Full Text] [Related]
3. The membrane-tubulating potential of amphiphysin 2/BIN1 is dependent on the microtubule-binding cytoplasmic linker protein 170 (CLIP-170).
Meunier B; Quaranta M; Daviet L; Hatzoglou A; Leprince C
Eur J Cell Biol; 2009 Feb; 88(2):91-102. PubMed ID: 19004523
[TBL] [Abstract][Full Text] [Related]
4. Expression and nuclear localization of ErbB3 in prostate cancer.
Koumakpayi IH; Diallo JS; Le Page C; Lessard L; Gleave M; Bégin LR; Mes-Masson AM; Saad F
Clin Cancer Res; 2006 May; 12(9):2730-7. PubMed ID: 16675564
[TBL] [Abstract][Full Text] [Related]
5. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
6. Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins.
Partin AW; Briggman JV; Subong EN; Szaro R; Oreper A; Wiesbrock S; Meyer J; Coffey DS; Epstein JI
Urology; 1997 Nov; 50(5):800-8. PubMed ID: 9372899
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical localization of prostate carcinoma-associated antigens.
Wright GL; Beckett ML; Starling JJ; Schellhammer PF; Sieg SM; Ladaga LE; Poleskic S
Cancer Res; 1983 Nov; 43(11):5509-16. PubMed ID: 6193873
[TBL] [Abstract][Full Text] [Related]
8. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Lucas JM; True L; Hawley S; Matsumura M; Morrissey C; Vessella R; Nelson PS
J Pathol; 2008 Jun; 215(2):118-25. PubMed ID: 18338334
[TBL] [Abstract][Full Text] [Related]
9. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
10. The cytoskeleton differentially localizes the early growth response gene-1 protein in cancer and benign cells of the prostate.
Mora GR; Olivier KR; Cheville JC; Mitchell RF; Lingle WL; Tindall DJ
Mol Cancer Res; 2004 Feb; 2(2):115-28. PubMed ID: 14985468
[TBL] [Abstract][Full Text] [Related]
11. Expression of differentially expressed nucleolar transforming growth factor-beta1 target (DENTT) in adult mouse tissues.
Martínez A; Ozbun LL; Angdisen J; Jakowlew SB
Dev Dyn; 2002 Jun; 224(2):186-99. PubMed ID: 12112471
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
Rehman I; Azzouzi AR; Cross SS; Deloulme JC; Catto JW; Wylde N; Larre S; Champigneuille J; Hamdy FC
Hum Pathol; 2004 Nov; 35(11):1385-91. PubMed ID: 15668896
[TBL] [Abstract][Full Text] [Related]
13. Cell specific expression of CD10/neutral endopeptidase 24.11 gene in human prostatic tissue and cells.
Song J; Aumüller G; Xiao F; Wilhelm B; Albrecht M
Prostate; 2004 Mar; 58(4):394-405. PubMed ID: 14968440
[TBL] [Abstract][Full Text] [Related]
14. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.
Uetsuki H; Tsunemori H; Taoka R; Haba R; Ishikawa M; Kakehi Y
J Urol; 2005 Aug; 174(2):514-8. PubMed ID: 16006883
[TBL] [Abstract][Full Text] [Related]
15. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence.
Seligson DB; Hongo F; Huerta-Yepez S; Mizutani Y; Miki T; Yu H; Horvath S; Chia D; Goodglick L; Bonavida B
Clin Cancer Res; 2007 Oct; 13(20):6056-63. PubMed ID: 17947468
[TBL] [Abstract][Full Text] [Related]
16. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
[TBL] [Abstract][Full Text] [Related]
17. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms.
Dong Y; Bui LT; Odorico DM; Tan OL; Myers SA; Samaratunga H; Gardiner RA; Clements JA
Endocr Relat Cancer; 2005 Dec; 12(4):875-89. PubMed ID: 16322328
[TBL] [Abstract][Full Text] [Related]
18. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor.
Sakamuro D; Elliott KJ; Wechsler-Reya R; Prendergast GC
Nat Genet; 1996 Sep; 14(1):69-77. PubMed ID: 8782822
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.
Sun A; Tawfik O; Gayed B; Thrasher JB; Hoestje S; Li C; Li B
Prostate; 2007 Feb; 67(2):203-13. PubMed ID: 17075831
[TBL] [Abstract][Full Text] [Related]
20. Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody.
Perk J; Gil-Bazo I; Chin Y; de Candia P; Chen JJ; Zhao Y; Chao S; Cheong W; Ke Y; Al-Ahmadie H; Gerald WL; Brogi E; Benezra R
Cancer Res; 2006 Nov; 66(22):10870-7. PubMed ID: 17108123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
